PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23377665-10	2013	These findings lay the groundwork as the basis of our first-in-human clinical trials of the nonviral SB system for the investigational treatment of CD19 B-cell malignancies (currently under 3 INDs: 14193, 14577, and 14739).	Antimony	101-103	CD19 molecule	Homo sapiens	148-152	
27491640-5	2017	CD19-CAR T cells engineered with our enhanced SB approach conferred potent reactivity in vitro and eradicated lymphoma in a xenograft model in vivo.	Antimony	46-48	CD19 molecule	Homo sapiens	0-4	
21451576-5	2011	In aggregate, SB100X improves SB transposition in primary human T cells and can be titrated with an SB transposon plasmid to improve the generation of CD19-specific CAR+ T cells.	Antimony	14-16	CD19 molecule	Homo sapiens	151-155